REN and diabetes mellitus: Interestingly, the PONTIAC (NT-ProBNP Guided Primary Prevention of CV Events in diabetic patients) trial showed that measuring NT-ProBNP levels could be a way to identify patients with diabetes in primary cardiovascular prevention that might benefit more from treatment with renin–angiotensin–aldosterone blockers and beta-blockers [20].